TITLE

Fomivirsen

AUTHOR(S)
Perry, C.M.; Barman Balfour, J.A.
PUB. DATE
March 1999
SOURCE
Drugs;Mar1999, Vol. 57 Issue 3, p375
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
▴ Fomivirsen (ISIS 2922) is an antisense oligonucleotide which specifically inhibits replication of human cytomegalovirus. It achieves this by binding to complementary sequences on messenger RNA transcribed from the major immediate-early transcriptional unit of the virus. It is being developed for the treatment of cytomegalovirus retinitis. ▴ Mean maximum retinal concentrations of fomivirsen occurred ≈2 days after a single intravitreal injection in monkeys. The elimination half-life of fomivirsen (after a single 115µg dose) in monkey retina was 78 hours. ▴ Fomivirsen, administered as an intravitreal injection, significantly delayed progression of cytomegalovirus retinitis in patients with AIDS in preliminary clinical trials. In 18 patients with newly diagnosed, unilateral, peripheral cytomegalovirus retinitis treated with fomivirsen 165µg once weekly for 3 weeks, then 165µg every second week, the median time to disease progression was significantly longer than in 10 patients in whom fomivirsen treatment was deferred until early disease progression (71 vs 14 days). ▴ In patients with advanced, refractory, sight-threatening disease, treatment with fomivirsen 330µg once weekly for 3 weeks and then 330µg every 2 weeks (n = 34) or 330µg on days 1 and 15 and then monthly (n = 20) significantly delayed disease progression. The interpolated median time to disease progression was 90 days in both treatment groups. ▴ The most common adverse events reported in clinical trials of fomivirsen were increased intraocular pressure and mild to moderate intraocular inflammation. These events were generally transient or reversible with topical steroid treatment.
ACCESSION #
9593153

 

Related Articles

  • CMV retinitis therapy updated. Mandava, Suresh // Ophthalmology Times;07/15/96, Vol. 21 Issue 20, p11 

    Presents advances in the treatment of cytomegalovirus (CMV) retinitis at the 1996 conference of the Association for Research in Vision and Ophthalmology. Treatment; Risks and complications.

  • CMV implant more effective than IV therapy.  // AIDS Patient Care & STDs;Dec97, Vol. 11 Issue 6, p458 

    States that sustained-release ganciclovir (Cytovene) intraocular implant (Vitrasert) delays the onset of CMV retinitis in people with acquired immunodeficiency syndrome (AIDS), as compared to standard IV therapy. Data published in `New England Journal of Medicine'; Details on the study; What...

  • Cytomegalovirus encephalitis in an HIV positive patient presenting with a cerebral mass lesion. Bassil, Habib F.; William, Daniel C. // AIDS Patient Care & STDs;Oct97, Vol. 11 Issue 5, p319 

    Presents information on Cytomegalovirus (CMV) and how it occurs as an infection in advance AIDS patients. Information on a patient with right-sided weakness due to CMV; Description of similar cases; Diagnoses of CMV.

  • CMV awareness hotline launched.  // Drug Topics;4/8/96, Vol. 140 Issue 7, p8 

    Cites the launching of a toll-free cytomegalovirus-prevention telephone hotline by the National Association of People with AIDS, to increase the awareness about the HIV-related cytomegalovirus disease.

  • Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS. Rahhal, Firas M.; Arevalo, J. Fernando // Annals of Internal Medicine;7/15/96, Vol. 125 Issue 2, p98 

    Focuses on study findings assessing the effectivity of using the drug, cidofovir in treating cytomegalovirus retinitis infections in AIDS patients. Administration of the drug using intravitreous infections; Degree of relief in patients suffering from the infection; Duration of the drug's...

  • 9-(1,3-dihydroxy-2-propoxymethyl) guanine (Ganciclovir) in the Treatment of Cytomegalovirus Gastrointestinal Disease with the Acquired Immunodeficiency Syndrome. Chachoua, Abraham; Dietrich, Douglas; Krasinski, Keith; Greene, Jeffrey; Laubenstein, Linda; Wernz, James; Buhles, William; Koretz, Stuart // Annals of Internal Medicine;Aug87, Vol. 107 Issue 2, p133 

    Presents a prospective therapeutic trial of 9-(1,3-dihydroxy-2-propoxymethyl) guanine triphosphate, or ganciclovir, to determine the clinical and virologic responses of cytomegalovirus gastrointestinal disease to the treatment of patients with AIDS. Pathologic conditions caused by...

  • Expression of the Late Cytomegalovirus (CMV) ppl50 Transcript in Leukocytes of AIDS Patients Is Associated with a High Viral DNA Load in Leukocytes and Presence of CMV DNA in Plasma. Boivin, Guy; Handfield, Julie; Toma, Emil; Lalonde, Richard; Bergeron, Michel G. // Journal of Infectious Diseases;5/1/99, Vol. 179 Issue 5, p1101 

    Reports that the expression of the late cytomegalovirus (CMV) pp150 transcript in leukocytes of AIDS patients is associated with a high viral DNA load in leukocytes and presence of CMV DNA in plasma. Expression of the late CMV transcript according to disease status and viral DNA load;...

  • Active retinitis in an infant with postnatally acquired cytomegalovirus infection. Piersigilli, F; Catena, G; De Gasperis, M R; Lozzi, S; Auriti, C // Journal of Perinatology;Jul2012, Vol. 32 Issue 7, p559 

    Congenital cytomegalovirus (CMV) is frequently associated with active retinitis. In contrast, in the immunocompetent neonate with postnatally acquired CMV infection retinitis is rarely present and usually does not progress. We describe the case of an infant with postnatal CMV infection and...

  • CMV retinitis: A clinical management update. Blanchet, Kevin D. // AIDS Patient Care & STDs;Apr96, Vol. 10 Issue 2, p86 

    Focuses on the treatment of cytomegalovirus (CMV) retinitis. Screening of patients with CMV infections; Drugs used in the treatment of CMV retinitis; Clinical trial on the best therapeutic regiment for CMV retinitis in relapsed patients; Management of side effects from therapy.

  • New CMV drug may have lower cost and risks. McCue, Mike // Ophthalmology Times;2/20/95, Vol. 20 Issue 8, p1 

    Reports on a new drug for cytomegalovirus retinitis called Vistide (cidofovir). Route of administration; Side effects; Advantages of the treatment.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics